Could Ozempic be used to treat Alzheimer’s disease?

Drug discovery and development Interviews Neuroscience

Emile Andriambeloson (left) is President and Head of Research at NEUROFIT (Illkirch, France). NEUROFIT is a preclinical contract research organization that provides clients with animal models to evaluate treatments, particularly for neurodegenerative and psychiatric disorders. Semaglutide, a glucagon-like peptide-1 receptor (GLP-1) agonist sold under brand names Ozempic and Wegovy, is used to treat type 2 diabetes and obesity. Millions of people worldwide now use these weight-loss ‘wonder drugs’, but their effects are not limited to metabolism. In this interview, Emile discusses a project that used animal models to see if semaglutide could be used to treat Alzheimer’s disease. Could you...

To view this content, please register now for access

Join our member community for FREE to access a collection of journal and online-only features, including:

  • Exclusive access to educational videos, eBooks and insights into top BioTechniques journal articles
  • The latest news and journal updates delivered straight to your inbox when you want it
  • Personalized recommendations for the latest member-exclusive podcasts, interviews and expert opinions
  • Priority registration to webinars, panel discussions and events
  • Access to competitions and journal publication discounts, including 10% off open access fees when you sign up today!